DOI: 10.12890/2025_005597
Transient dysarthria and hemiparesis in an adolescent
Authors
y.yanagita@gmail.com
Keywords
Paroxysmal kinesigenic dyskinesia, transient hemiparesis, dysarthria kinesigenic triggerAbstract
An adolescent male in his teens had recurrent episodes of transient left lower limb weakness, persisting for three years. These episodes were consistently triggered by specific movements, such as postural changes or movement initiation, occurring multiple times per day. The patient adapted his behaviour to avoid triggering symptoms. Based on the clinical presentation, paroxysmal kinesigenic dyskinesia was diagnosed. Although dysarthria is uncommon in paroxysmal kinesigenic dyskinesia, its presence in this case highlights the condition’s clinical variability. Carbamazepine therapy was initiated, which resulted in a significant reduction in the frequency of episodes. This case underscores the importance of recognising movement-triggered transient motor symptoms, including rare symptoms such as dysarthria, to prevent misdiagnosis and unnecessary testing. Early recognition and treatment can significantly improve outcomes and quality of life in patients with paroxysmal kinesigenic dyskinesia.
References
- Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004;63:2280–2287. doi: 10.1212/01.wnl.0000147298.05983.50
- Sun W, Li J, Zhu Y, Yan X, Wang W. Clinical features of paroxysmal kinesigenic dyskinesia: report of 24 cases. Epilepsy Behav 2012;25:695–699. doi: 10.1016/j.yebeh.2012.06.019
- Bhatia KP. Paroxysmal dyskinesias. Mov Disord 2011;26:1157–1165. doi: 10.1002/mds.23765
- Mehta SH, Morgan JC, Sethi KD. Paroxysmal dyskinesias. Curr Treat Options Neurol 2009;11:170–178. doi: 10.1007/s11940-009-0020-x
- Cao L, Huang X, Wang N, Wu Z, Zhang C, Gu W, et al. Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China. Transl Neurodegener 2021;10:7. doi: 10.1186/s40035-021-00231-8